You are viewing: South Korea Antibody Therapeutics Market analysis
Part of: Antibody Therapeutics Market (Global)

The South Korea Antibody Therapeutics Market was valued at $2080 Million in 2026 and projected to reach to $2810 Million by 2031, representing a compound annual growth rate of 3.4%. South Korea's antibody therapeutics market is poised for sustained growth through 2031, supported by the country's commitment to biopharmaceutical innovation and healthcare advancement.

South Korea Antibody Therapeutics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Antibody Therapeutics Market Trends and Insights

  • South Korea's advanced healthcare infrastructure and strong biopharmaceutical sector position the country as a key player in the Asia Pacific antibody therapeutics landscape.
  • The market growth in South Korea is driven by increasing prevalence of chronic diseases, rising healthcare expenditure, and growing adoption of monoclonal antibody therapies across oncology, immunology, and infectious disease indications.
  • South Korea's regulatory environment and investment in biotechnology innovation continue to support market expansion through 2031..

Key Market Statistics

  • CAGR (2026-2031) 3.4% CAGR
  • Market Size, 2026 ~USD 2080 Million
  • Forecast, 2031 ~USD 2810 Million
  • Country South Korea

South Korea Antibody Therapeutics Market Overview

Market Size & Growth :

South Korea's antibody therapeutics market is valued at USD 2,080 million in 2026, expanding to USD 2,810 million by 2031 at a CAGR of 3.4%, reflecting steady growth in the region's biopharmaceutical sector.

Advanced Healthcare Infrastructure :

South Korea boasts one of Asia's most sophisticated healthcare systems with strong regulatory frameworks, high healthcare spending, and rapid adoption of innovative therapeutic solutions, supporting antibody drug development and commercialization.

Biopharmaceutical Excellence :

The country hosts a robust biopharmaceutical ecosystem with leading research institutions, contract manufacturing organizations (CMOs), and innovative biotech companies specializing in monoclonal antibody development and production.

Regional Market Position :

South Korea represents a significant market within the Asia Pacific antibody therapeutics landscape, driven by increasing prevalence of cancer, autoimmune diseases, and growing patient access to advanced biologic therapies.

South Korea Antibody Therapeutics Market Dynamics

  • The market benefits from strong government support for R&D, increasing clinical trial activities, and expanding manufacturing capabilities for monoclonal antibodies and biosimilars.
  • Rising incidence of chronic diseases and aging demographics will drive demand for targeted antibody-based treatments.
  • South Korea's strategic position as a manufacturing hub for Asia Pacific, combined with its skilled workforce and regulatory expertise, positions the country favorably for market expansion.
  • However, growth remains moderate compared to global rates, reflecting market maturity and competitive pricing pressures in the region..

Market Ecosystem

logo-mobile

ANTIBODY THERAPEUTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Administered teclistamab, a BCMA×CD3 bispecific antibody for relapsed/refractory multiple myeloma, using a hospital-based step-up dosing model. Supports safe administration of complex bispecific antibodies, reduces serious toxicity risk through specialist monitoring, and creates a practical hospital-to-clinic care pathway for high-value antibody therapeutics.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • South Korea's antibody therapeutics market will grow from USD 2,080M (2026) to USD 2,810M (2031) at a 3.4% CAGR.
    • South Korea benefits from a mature healthcare system and robust biopharmaceutical manufacturing capabilities supporting antibody drug development.
    • Oncology and immunology remain the dominant therapeutic areas driving antibody therapeutics adoption in South Korea.
    • South Korea's regulatory framework and government support for biotech innovation position it as a regional hub for antibody therapeutic commercialization.

    Antibody Therapeutics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment PIPELINE PRODUCTS (Product)
    Forecast Period 2026-2031
    Growth Rate CAGR of 7.5% from 2026 to 2031
    Largest Segment COMMERCIALIZED PRODUCTS (Product)
    Market Size Base Year (Billions) ~USD 311.44 (2026)
    Revenue Forecast (Billions) ~USD 447.11 (2031)
    Segments Covered Product, Type, Format, Payload Type, Target, Source, Route Of Administration, Therapeutic Area, End User

    South Korea Antibody Therapeutics Market Report Segmentation

    9 segment dimensions are covered across the global market.

    By Product

    • Commercialized Products
    • Pipeline Products

    By Type

    • Darzalex
    • Dupixent
    • Ivonescimab
    • Izalontamab Brengitecan
    • Keytruda
    • Other Commercialized Products
    • Other Pipeline Products
    • Sacituzumab Tirumotecan (Sac-Tmt)
    • Skyrizi
    • Vyvgart

    By Format

    • Antibody Drug Conjugates (Adcs)
    • Antibody Fragments
    • Antibody-Drug Conjugates
    • Bispecific Antibodies
    • Monoclonal Antibodies
    • Other Antibody Therapeutics
    • Other Formats
    • Polyclonal Antibodies

    By Payload Type

    • Dm1
    • Dm4
    • Mmae
    • Other Payload Types
    • Sn-38

    By Target

    • Cytokine/Inflammatory Pathway Targets
    • Her2
    • Other Targets
    • Pd-1/Pd-L1
    • Tnf Alpha

    By Source

    • Chimeric
    • Human
    • Humanized
    • Other Sources

    By Route Of Administration

    • Intravenous
    • Other Routes Of Administration
    • Subcutaneous

    By Therapeutic Area

    • Autoimmune & Inflammatory Diseases
    • Bone Disorders
    • Hematology
    • Immunology
    • Infectious Diseases
    • Neurology
    • Oncology
    • Osteology
    • Other Therapeutic Areas

    By End User

    • Hospitals & Specialty Care Centers
    • Long-Term Care Facilities
    • Other End Users

    Target Audience

    • Pharmaceutical & Biotech Companies : Manufacturers and developers of antibody therapeutics need South Korea-specific market data to evaluate market entry opportunities, competitive positioning, and revenue forecasting in this advanced healthcare market.
    • Investment & Private Equity Firms : Investors targeting the Asia Pacific biopharmaceutical sector require detailed South Korea market analysis to identify growth opportunities, assess portfolio companies, and make informed capital allocation decisions.
    • Healthcare Consultants & Advisors : Strategy consultants supporting clients in the antibody therapeutics space need South Korea-specific insights to develop market entry strategies, competitive analyses, and business development recommendations.
    • Contract Manufacturing Organizations (CMOs) : CMOs and contract development organizations require South Korea market intelligence to understand demand for antibody manufacturing services, identify client opportunities, and plan capacity expansion.
    • Healthcare Policy & Regulatory Bodies : Government agencies and regulatory organizations need market data on South Korea's antibody therapeutics sector to inform healthcare policy, reimbursement strategies, and biopharmaceutical industry development initiatives.

    Reasons to Buy this Report

    • Market Size & Forecast Data : Access precise market valuations for South Korea (USD 2,080M in 2026, USD 2,810M in 2031) with detailed CAGR analysis to support investment decisions and business planning in the region.
    • Competitive Landscape Intelligence : Understand South Korea's biopharmaceutical ecosystem, including leading manufacturers, CMOs, and biotech innovators developing antibody therapeutics, enabling strategic partnerships and market entry strategies.
    • Regulatory & Healthcare Insights : Gain comprehensive knowledge of South Korea's advanced regulatory environment, healthcare infrastructure, and reimbursement policies specific to antibody therapeutics for market navigation.
    • Growth Driver Analysis : Identify key market drivers in South Korea including disease prevalence trends, aging demographics, clinical trial activities, and manufacturing capabilities influencing antibody therapeutics adoption.
    • Regional Market Positioning : Benchmark South Korea's market performance within Asia Pacific, understand its role as a manufacturing hub, and identify opportunities for expansion in this strategically important biopharmaceutical market.

    Frequently asked questions

    What is the current size of South Korea's antibody therapeutics market?

    South Korea's antibody therapeutics market is valued at USD 2,080 million in 2026.

    What is the projected market size for South Korea's antibody therapeutics by 2031?

    South Korea's antibody therapeutics market is projected to reach USD 2,810 million by 2031.

    What is the CAGR for South Korea's antibody therapeutics market?

    South Korea's antibody therapeutics market is expected to grow at a CAGR of 3.4% from 2026 to 2031.

    Which therapeutic areas dominate South Korea's antibody therapeutics market?

    Oncology and immunology are the primary therapeutic areas driving antibody therapeutics adoption in South Korea.

    What factors are driving growth in South Korea's antibody therapeutics market?

    Key growth drivers in South Korea include increasing chronic disease prevalence, rising healthcare spending, advanced regulatory infrastructure, and strong biopharmaceutical innovation capabilities.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global antibody therapeutics market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.

    Secondary Research

    Secondary research was used primarily to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, the World Health Organization (WHO), the United States Food and Drug Administration (US FDA), the National Center for Biotechnology Information (NCBI), and regulatory body websites, among others. These sources also provided key information on major players, market classification, and segmentation aligned with industry trends, regional and country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Antibody Therapeutics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the antibody therapeutics market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

    Antibody Therapeutics Market : Top-Down and Bottom-Up Approach

    Antibody Therapeutics Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size through the estimation process, the total market was segmented into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Therapeutic antibodies are targeted biopharmaceuticals that trigger a biological response. Therapeutic antibodies are drugs that use antibodies, which play a significant role in the body's innate immune system. Antibodies are produced by B cells, a type of immune cell, to attack foreign substances (antigens) in response to infections or allergens. Since antibodies recognize and attack only specific antigens, these properties are leveraged to generate genetically engineered antibodies (chimeric, humanized, fully human, engineered fragments & bispecific) designed to target and neutralize specific disease markers.

    Key Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty care centers
    • Regulatory agencies
    • Health insurers and payers
    • Private and government-funding organizations

    Report Objectives

    • To define, describe, and forecast the global antibody therapeutics market by product, format, target, source, route of administration, therapeutic area, end user, and region
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall antibody therapeutics market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
    • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically analyze the market structure and profile the key players of the global antibody therapeutics market, and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the antibody therapeutics market

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

    Portfolio Assessment

    • Product Matrix gives a detailed comparison of the product portfolios of the top five companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographical Analysis

    • Further breakdown of the Rest of Europe market, by country
    • Further breakdown of the Rest of Asia Pacific market, by country

     

    Get the Full Antibody Therapeutics Market Report

    Full forecast, segment splits, and company analysis for all Antibody Therapeutics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status